Our Team
Executive Team
David Davies
Chief Executive Officer
Prior to joining Oncocidia, David was the Managing Director of bio-medical development group CetroMed and a director of its therapeutic and medtech subsidiaries. Previously he was Head of Corporate Finance at Peel Hunt, where he spearheaded the extension of his team into the life-sciences sector. He was earlier with Deloitte Corporate Finance, having qualified as a chartered accountant in 1986. He has a BA from Cambridge University.
Don Daley, PhD
Chief Scientific Officer
Don has 25 years’ experience leading drug discovery and development projects. He was Global Head of Physical and Structural chemistry for SANOFI, and co-founder of Argenta Discovery, a successful spin-out from Aventis. He has a PhD from Cambridge University.
Barnaba Lyzbicki, PhD
Executive Business Manager
Barnaba, a highly qualified researcher and analyst, participates in Oncocidia’s scientific as well as business development activities. He was previously a Visiting Scientist at the University of California, San Francisco, and with the global CRO firm IQVIA. He has a PhD in Biotechnology, Pharmacology & Toxicology from the University of Bologna and a PharmD from the Jagellonian University, Krakow.
Scientific Research Team
Yicheng Ni, MD, PhD
Dr. Ni is a pioneer in cancer therapies leading to clinical practice, including the treatment of tumors by radio frequency ablation. He is holder of the Bayer Chair and Head of the Theragnostics Laboratory at KU Leuven, where he continues to refine the Oncocidia approach. He and the Oncocidia therapy strategy are recipients of multiple awards and honours. He holds a PhD from KU Leuven and an MD from Nanjing Medical University, China.
Shuncong Wang, MD
Research Scientist
Dr. Wang is a researcher at the Theragnostics Laboratory, KU Leuven, undertaking studies under the leadership of Dr. Ni into applicability of Oncocidia to early-stage (pre-vascular) tumors. He holds an MD degree from Sun Yat-sen University, China.
Non-executive
Charles Jonscher, PhD
Chairman
Charles is Founder and President of the London-based corporate finance and M&A firm CET, and was previously head of the European TMT Practice at Booz Allen & Hamilton. He is also with the Institute of Health Metrics and Evaluation at the University of Washington, and was formerly with the Faculty of Economics at Harvard University and at MIT.